INTRODUCTION
In 1952, Conley and Hartmann (1) called attention to a coagulation inhibitor in patients with systemic lupus erythematosus (SLE).' Similar inhibitors have been de-A preliminary report of this research was presented at the 22nd meeting of the American Society of Hematology, Phoenix, Arizona, and published in abstract form in 1979. Blood. 54: 306A.
Receivedfor publication 17 March 1980 and in revisedform 20 May 1980. 'Abbreviations used in this paper: PA, phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine; RVV, Russell's viper venom; SLE, systemic lupus erythematosus.
scribed in a variety of diseases (2) (3) (4) (5) . The presence of such an inhibitor, to which the term "lupus anticoagulant" has been applied, is characterized by the impaired conversion of prothrombin to thrombin, most frequently reflected in the prolongation of prothrombin and partial thromboplastin times. The immunoglobuliin nature of these anticoagulants has been demonstrated but their precise mechanism of action has not been delineated (2) (3) (4) (5) . Individuals with lupus anticoagulants rarely have deficiency of only a single coagulation factor, although hypoprothrombinemia has been reported occasionally (3) , and no specific coagulation factor inhibition has been demonstrated for such anticoagulants.
We have studied a patient with macroglobulinemia and a lupus-type anticoagulant whose purified monoclonal IgMX paraprotein possessed the anticoagulant activity. We have demonstrated that the mechanism of coagulation inhibitior is the result of a specific immunologic reaction wit'i acidic phospholipids. pension in the column buffer followed by Sephadex G-200 gel filtration and ultrafiltration. This material was used only in some coagulation systems and was not passed through the anti-a2-macroglobulin immunoadsorbent column.
Purification of prothrombin and Factor X. Human prothrombin and Factor X were purified from cryosupernate according to the method of Miletich et al. (6) with the following modifications. After barium citrate adsorption, ammonium sulfate elution, and quaternary aminoethyl-Sephadex chromatography, the eluate was dialyzed overnight at 4°C against a buffer consisting of 0.05 M imidazole, 0.001 M benzamadine, pH 7.0, and applied to a 2 x 30-cm column of dextran sulfate-Sepharose 4B (7) equilibrated with the same buffer. A 1-liter linear gradient of NaCl (0.0-1.0 M) was used to develop the column. Prothrombin elutes first (0.05 M NaCl), followed by Factor X (0.3 M NaCI) and then Factor IX (0.55 M NaCl).
The Factor X peak was pooled and dialyzed against 0.2 M potassium phosphate, pH 6.8, and applied to a 0.7 x 56-cm column of hydroxyapatite (Bio-Rad Laboratories, Richmond, Calif.). Factor X was eluted with 20 ml of 0.27 M potassium phosphate, pH 6.8, as described by Rosenberg et al. (8) . The fractions containing Factor X activity were pooled, ultrafiltered to a concentration of 1-2 mg/ml, quick-frozen with acetone dry ice, and stored at -70°C. The preparation contained -200 Factor X U/mg and was at least 95% pure as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Factor Xa was prepared by incubation of Factor X for 15 min at 37°C with 1% (wt/wt) purified Factor X-converting enzyme from Russell's viper venom (RVV) in 0.15 M NaCI, 0.02 M Tris, and 0.007 M CaC12, pH 7.4. The purified Factor X-converting enzyme was a gift from Dr. B. Furie, Tufts University School of Medicine, Boston, Mass.
Tryptic hydrolysis of IgM. Tryptic cleavage of IgM was carried out at 65°C according to the method of Plaut and Tomasi (9) . Tryptic cleavage at this temperature produces intact Fab,, and FC5, fragments. In a typical experiment, 10 ing of IgM in 6.6 ml of a pH 8.1 buffer consisting of 0.15 M NaCl, 0.05 M Tris, and 0.0115 M CaCI2 was preincubated in a 65°C water bath until the temperature of the solution reached 65°C, at which time 0.5 mg of twice-crystallized N-a-p-tosyl-L-lysine chloromethyl ketone trypsin (Worthington Biochemical Corp., Freehold, N. J.) in 100 ,ul of water was added. At the end of exactly 7.5 min, the incubation mixture was cooled in an ice-water bath. The cleaved fragments were separated on a 2 x 90-cm Sephadex G-200 column using a buffer containing 0.05 M Tris and 0.15 M NaCl, pH 8.1. The FabM, and FC5 peaks were pooled and concentrated against 20% polyethylene glycol (PEG 20,000; Fisher Scientific Co., Pittsburgh, Pa.). The concentrated peaks were immunologically pure when tested by Ouchterlony double diffusion against antibodies to Fc, and Fab (Atlantic Antibodies).
Phospholipid binding by prothrombin and Factor X. Ca++-dependent binding of prothrombin and Factor X to phospholipid micelles was studied by the method of Gitel et al. (10) , with some modifications: 12.5 mg of phospholipid (Centrolex P; Central Soya Co., Inc., Fort Wayne, Ind.) was suspended in 5 ml buffer (0.1 M NaCl, 0.04 M Tris, pH 7.4) in a glass ampule. The suspension was deaerated by bubbling with dry nitrogen for 40 Innfunodiffusiorn of IgM against phospholipids. Chromatographically pure phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylcholine (PC), and phosphatidic acid (PA) dissolved in chloroform-methanol were obtained from Supelco, Inc. (Bellefonte, Pa.). 1 mg of each phospholipid was dried in a stream of dry nitrogen in a small glass ampule, suspended in 1 ml of buffer (0.15 M NaCl, 0.02 M Tris, pH 7.4), and bubbled with dry nitrogen for 40 min. The ampules were sealed and the phospholipids sonicated and centrifuged as described above. The supernates were diluted in the same buffer to a final absorbance at 320 nm of 0.066. These preparations were used for immunodiffusion studies in 1% agarose gel in a buffer containing 0.15 M NaCl and 0.08 M Tris, pH 7.4 (11) . Patient and control IgM were used at a concentration of 1 mg/ml. In some experiments, patient Fab, was mixed with specific phospholipids before immunodiffusion against patient IgM. Precipitin lines were stained for protein with Coomassie Blue for phospholipid with Sudan black B.
Platelet-Factor Xa binding studies. Factor Xa binding to thrombin-treated platelets was studied according to the method of Miletich et al. (6) , except that some incubation mixtures contained 1 mg/ml of patient or control IgM. Correction for nonspecific binding was done according to the methods of these authors. Purified human thrombin used in these experiments was a gift from Dr. John Fenton, New York State Department of Health Laboratories, Albany, N. Y.
Protein iodination. Prothrombin was iodinated by the iodine monochloride method, as described (12) , to a specific activity of 1.3 x 106 cpm/Lg. Factor X was iodinated as described by Miletich et al. (6) were mixed with 1 mCi of nitrogen-dried reagent (1,500 Ci/mM) for 15 min in an ice bath. Unbound reagent was removed by gel filtration on a 0.5 x 5-cm column of Sephadex G-25 equilibrated with a pH 7.4 buffer containing 0.15 M NaCl and 0.02 M Tris, and further dialyzed against the same buffer. The specific activity of Factor X was 4 x 106 cpm/U, corresponding to -1,000 cpm/ng.
Protein concentration was determined from absorbance at 280 nm and corrected for scattering as described (13) , with the following A2801c values: prothrombin 13.6 (13), Factor X 11.6 (6), and IgM 11.8 (9) .
Coagulation studies. Venous blood was collected into 0.1 vol of 3.8% trisodium citrate; plasma was obtained by centrifugation at 2,300g at 4°C for 15 min. Routine coagulation studies and coagulation factor assays were done by conventional methods (14, 15) . Taipan venom times were performed as described by Pirkle et al. (16) , and Echis carinatus times were performed as described by Franza et Platelet-rich plasma was obtained by centrifugation of citrated venous blood at 180 g for 15 min at 22°C. The platelets were sedimented by further centrifugation at 22°C, 1,500 g, for 15 min. The supernate plasma was removed and the platelet pellet suspended in a buffer consisting of 0. 15 M NaCl, 0.02 M Tris, and 1 mM EDTA, pH 7.4. The platelets were washed three times in the same buffer by sedimentation for 15 min at 1,200 g and finally suspended at a concentration of 200,000 platelets/,ul in a buffer consisting of 0. 15 M NaCl and 0.02 M Tris, pH 7.4, containing 1 mg/ml of glucose.
All coagulation factor assays, using either phospholipid or washed platelets, were performed using 1:5, 1: 10, and 1:20 dilutions of patient or standard normal plasma. When phospholipid was used, patient plasma dilution curves were not parallel to the standard curve; assay results are based on the 1:20 dilution only.
Clinical summary. The patient was a 72-yr-old man in good health until March 1978 when he began to have episodes of epigastric distress and noted a 10-lb wt loss. He had no past history of spontaneous bleeding or excessive bleeding with surgery, and did not have a bleeding tendency at the time of diagnosis or throughout the course of his illness. On physical examination he had splenomegaly and hepatomegaly but no lymphadenopathy. His blood count showed: hemoglobin 11.8 gm/dl, platelets 235,000/s.I, leukocytes 5,700/gl with 34% neutrophils, 8% bands, 47% lymphocytes, 8% atypical lymphocytes, and 3% monocytes. The bone marrow was hyperplastic and infiltrated with lymphocytes. There was an IgMA paraprotein present in his serum, with a concentration ranging between two and three gm/dl during the course ofthe illness. He died 1.5 yr after the initial diagnosis. At autopsy he had disseminated lymphoma but no evidence of internal or external hemorrhage.
RESULTS
Coagulation tests. Results of the screening coagulation tests are shown in Table I . The prothrombin, partial thromboplastin, RVV, and Taipan snake venom times were prolonged, whereas the Echis carinatus and thrombin times were normal. All but the latter two tests have a requirement for phospholipid. The whole blood coagulation time was also normal. Prolongation of the prothrombin time was independent of the tissue or species source of tissue factor. Prolongation of the partial thromboplastin time was present both in activated and in nonactivated systems; this effect was less obvious with human brain extract. The bleeding time, platelet count, and platelet aggregation studies were entirely normal.
Addition of the patient's purified monoclonal IgM paraprotein to normal plasma reproduced all the coagulation abnormalities seen in the patient's plasma (Table II) . Addition of control monoclonal IgM had no effect. Inhibition ofcoagulation tests could be achieved by addition to normal plasma of patient Fab, but not FcS,M (Table II) the presence of patient Fab,, (Fig. 1) , binding of prothrombin and Factor X to phospholipid was almost completely blocked.
Immunologic specificity of patient IgM towards phospholipid. The immunologic specificity of patient IgM toward individual phospholipids is shown in Fig. 2A . A strong precipitin line is present against PS, PI, and PA, but no reaction is seen against PC or PE. Neither control monoclonal nor normal polyclonal IgM showed any reaction in this system. The positive precipitin reactions could be completely blocked by prior addition of patient Fab,, to the phospholipids (Fig. 2B) (Table III) . Similarly, apparent deficiencies of several coagulation factors disappeared when onestage assays were performed using washed platelets instead of phospholipids (Table IV) . Control congenitally deficient plasmas gave the same results when assayed either with phospholipid or platelets. Both normal and patient platelets were effective, as were also platelet preparations frozen and thawed five times.
Effect of patient IgM on Factor Xa-platelet interaction. Patient IgM had no effect on the binding of Factor Xa to platelets, the binding curve being superimposable with that found in the presence of control Tris-NaCl buffer, pH 7.4 albumin, 1 mg/ml glucos determined after 30 min trol monoclonal IgM; 0, uffer alone (Fig. 3) . Consistent an IgM paraprotein with specificity against phosphoryl-)ns, high specific radioactivity choline has also been described (29) . No (2) (3) (4) (5) .
The nature of the phospholipid involvement in cohave been reported in a variety agulation has been the subject of controversy (32, 33) .
espite the abnormalities in co-Our current concept is that negatively charged phostimes of a marked degree, the pholipid micelles function as a surface upon which Lnticoagulant, per se, is seldom both the activation of Factor X by Factor IXa in the eding tendency (1) (2) (3) (4) (5) . In fact, presence of Factor VIII and the activation of proreported in at least 13 patients thrombin by Factor Xa in the presence of Factor V ants (20) (21) (22) , one of whom has can occur. Factor X and prothrombin each bind to ited with warfarin sodium with-negatively charged phospholipid micelles in a process )lications (20) . The nature of the with a complex requirement for calcium ions; yn of coagulation tests is not carboxyglutamic acid residues, whose presence in ggested by several investigators these proteins is dependent on vitamin K action, are tivity might be directed toward required for Ca++-binding and subsequent binding to ponent involved in prothrombin phospholipid (34) . Factor Xa has also been shown to lthough no direct evidence for bind to phospholipid by a similar mechanism (35) . It adduced. is likely that Factor IXa behaves in an analogous manpholipids and related substances ner, although no evidence for such binding exists at this ion, although their precise im-time. Factor V also binds to phospholipid, but this rly understood (24) . Antibodies reaction does not depend on the presence of calcium ids have been raised in experi-ions (35, 36) . It is not known whether Factor VIII ny cases these antibodies cross-binds to phospholipid, although some early preparaholipids besides the immunizing tions of this clotting factor were rich in phospholipid, nany myeloma proteins derived suggesting a possible interaction (37) . Thus, minimal ed plasma cell tumors in BALB/c requirements have been demonstrated for prothromlcholine specificity (25) . Mono Because phospholipids can substitute for platelets in prothrombin conversion and in various in vitro coagulation assays, it has been assumed that platelets promote prothrombin conversion by providing phospholipid at their surface. This activity has been referred to as platelet Factor 3 (39) . Several lines of argument lead to questioning of this hypothesis. Marcus et al. (40) suggested that more than phospholipid was involved in platelet Factor 3 activity because 20 times more extracted platelet phospholipid was required to achieve the same clotpromoting activity as that produced by intact platelet membranes. Moreover, PS, the most active phospholipid in vitro, is apparently present largely or exclusively on the inner aspect of the platelet membrane (41) . There is little evidence, in general, that "flip-flop" translocation of membrane phospholipids occurs at a significant rate (42, 43) , and conflicting evidence suggests that platelet membrane PS becomes exteriorized in response to platelet aggregating agents (41, 44) . Finally, Factor X and prothrombin, though they bind to negatively charged phospholipid micelles in vitro, have not been found to bind to platelet membranes (45, 46) . Nevertheless, the concept that the platelet membrane may serve as a surface upon which prothrombin activation occurs finds strong support in the work of Miletich et al., who have demonstrated the formation of a high affinity Factor Xa binding site on the surface of platelets (46) . The receptor has the properties of activated Factor V and has a higher affinity for Factor Xa than the affinity of phospholipid micelles for Factor X (6). Receptor-bound Factor Xa can generate thrombin from prothrombin in the absence ofadded phospholipids. The in vivo significance of this mechanism is indicated by the finding by the same authors of a better correlation of the bleeding tendency in Factor V deficiency with platelet Factor V than with plasma Factor V (47) , and also by the recent report of a patient with a hemorrhagic diathesis who has normal plasma and platelet Factor V but a deficiency of platelet Factor Xa binding sites (48) . It appears that the sole requirement for formulation of the Factor Xa binding site is the activation of Factor V because Factor Xa is able to bind to intact (unstimulated) platelets in the presence of Factor Va (49) . It is known that Factor Va can bind with high affinity to platelets (50) and prothrombin (51) , and binding of Factor Va to Factor Xa on a mole-formole basis can be inferred from kinetic data. (52) . immunodiffusion. The Fab, was ofhigh enough specific radioactivity to detect as few as 200 PS residues/platelet. Thus, the head group of PS may be relatively inaccessible in cell membranes even when the inner, PS-rich, membrane surface is exposed, a possibility also suggested by the inability of chemical probes such as 2,4,6-trinitrobenzenesulfonate to bind >50-60% of the PS present in erythrocyte membranes (53) . The inaccessibility of phospholipid head groups in cell membranes is further suggested by the observations that neither animals nor humans with circulating antibodies to phospholipid polar head groups show any evidence of general cellular destruction or dysfunction, even when the antibody is directed against the head group of PC, a phospholipid known to be on the external surface of cell membranes (53) .
The present case defines a new mechanism of action for a coagulation inhibitor. The anticoagulant mechanism delineated here is not restricted to this patient. Preliminary results in our laboratory on the plasmas from three patients with SLE or SLE-like illnesses and lupus-type anticoagulants have revealed the presence of anti-PS and anti-PA reactivity in their immunoglobulin fractions and correction ofthe plasma coagulation defect by platelets. Whether this mechanism is generally applicable to all lupus anticoagulants remains to be determined. Our observations provide an explanation for the dissociation of abnormal tests and normal in vivo hemostasis in our patient and perhaps in others, and give strong support to the central role of platelets in the coagulation mechanism. Nevertheless, they raise several fundamental questions: What, if any, is the role of phospholipid in coagulation in vivo? How do the y-carboxyglutamic residues of the vitamin Kdependent coagulation factors, whose function is based entirely on the phospholipid micelle model but whose absence is associated with a bleeding tendency, operate in vivo? Why are phospholipid head groups partially or completely unavailable to some chemical and immunologic probes, despite the fact that the classical membrane model predicts that they would be available? We anticipate that the study of lupus anticoagulants may be useful for approaching some of these problems.
